News from Novo Nordisk Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 14, 2017, 12:12 ET Anthony Anderson, Star of ABC's "black-ish," Partners with Novo Nordisk to Launch "Get Real About Diabetes™"

Anthony Anderson, star of ABC's hit comedy "black-ish," wants to help people get real about diabetes. Today on World Diabetes Day, he kicks off...


Nov 08, 2017, 11:14 ET "Diabetes 360" Survey Shows Patients Want More Than Medicine, Need Emotional Support

Major portions of the American population with diabetes believe that their care requires much more than medicine, including emotional support and...


Oct 31, 2017, 08:00 ET New US study reveals key reasons why millions of people with obesity are not receiving adequate care

Few of the more than 90 million Americans1 with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness,...


Oct 26, 2017, 02:00 ET Global City Leaders: Cut Obesity By A Quarter To Prevent 100M New Diabetes Cases By 2045

An international coalition of cities is calling for an ambitious global goal to prevent more than 100 million new cases of diabetes by 2045. The...


Oct 18, 2017, 17:34 ET Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide

Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA)...


Sep 29, 2017, 11:03 ET Novo Nordisk Receives FDA Approval for Fiasp®, a New Fast-Acting Mealtime Insulin

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp® (insulin aspart injection) 100 Units/mL, a...


Sep 29, 2017, 02:00 ET IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes

- Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of...


Sep 26, 2017, 12:51 ET Working Mother names Novo Nordisk one of its "100 Best Companies"

Novo Nordisk in the U.S. has been named to the "Working Mother 100 Best Companies" list which recognizes companies for their strong leadership in...


Sep 05, 2017, 17:10 ET Novo Nordisk announces conclusion of U.S. federal investigation of marketing practices

Today, Novo Nordisk announced it has reached a resolution with the U.S. federal government and the states about an investigation launched in...


Aug 25, 2017, 12:18 ET Victoza® (liraglutide) is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular events

The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza® (liraglutide) to reduce the risk of major adverse...


Jul 12, 2017, 11:05 ET Novo Nordisk and Glooko advance their digital health collaboration with launch of unique integrated app for improved diabetes management

Novo Nordisk and Glooko have announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more...


Jul 05, 2017, 15:30 ET Novo Nordisk recalls cartridge holders in certain NovoPen Echo® insulin delivery devices due to potential health risks

Novo Nordisk is initiating a recall of insulin cartridge holders used in a small number of NovoPen Echo® batches because they may crack or break if...


Jun 20, 2017, 18:57 ET Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes

Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA)...


Jun 12, 2017, 17:15 ET Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial

Novo Nordisk today announced the primary results from DEVOTE – the first randomised, double-blind, treat-to-target, event-driven trial comparing...


Jun 10, 2017, 21:00 ET Xultophy® 100/3.6 demonstrated similar A1C reductions with significantly lower rates of hypoglycemia and a decrease in weight vs basal-bolus therapy

New results from the phase 3b DUAL VII clinical trial showed that Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and...


Jun 06, 2017, 08:20 ET Novo Nordisk to present 60 abstracts at 77th Annual American Diabetes Association Scientific Sessions in San Diego, CA

Novo Nordisk, a global leader in diabetes care, today announced that data from 60 abstracts will be shared at the upcoming 77th annual Scientific...


May 31, 2017, 17:32 ET FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN®...


May 04, 2017, 10:45 ET Heart attacks, strokes and other major health events play key role in driving older Americans with obesity to address their weight

A statistically significant greater proportion of older people with obesity (PwO) (16%) than younger ones (12%) reported that a specific medical...


May 03, 2017, 10:15 ET Novo Nordisk Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in the United States

Novo Nordisk, a world leader in diabetes care, today announced the availability of its new combination therapy Xultophy® 100/3.6 (insulin degludec...


Apr 27, 2017, 11:06 ET Novo Nordisk Receives FDA Approval of Saxenda® (liraglutide) injection 3 mg Label Update Including Long-Term Safety and Efficacy Data from 3-Year Trial

Novo Nordisk today announced that the US Food and Drug Administration (FDA) approved an updated product label for Saxenda® (liraglutide) injection...


Apr 17, 2017, 09:33 ET Novo Nordisk Invites the Community to Unmask Everyday Heroes in Recognition of World Hemophilia Day

Not every hero wears a cape or has super powers. In the hemophilia community, many perform heroic acts to help knock down barriers and unite each...


Mar 09, 2017, 09:04 ET Novo Nordisk Named on the FORTUNE 100 Best Companies to Work For® List for Ninth Consecutive Year

Novo Nordisk in the U.S. has ranked #73 on the FORTUNE "100 Best Companies to Work For®" list, marking the ninth consecutive year it has been...


Feb 09, 2017, 09:33 ET Great Place to Work® and Fortune Name Novo Nordisk as one of the country's best workplaces for giving back

Great Place to Work® and Fortune today recognized Novo Nordisk in the United States as one of the country's "Best Workplaces for Giving Back." Novo...


Dec 19, 2016, 14:00 ET Novo Nordisk Receives FDA Approval of Tresiba® (insulin degludec injection 100 U/mL, 200 U/mL) for Use in Children and Adolescents With Diabetes

Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for...


Dec 07, 2016, 09:36 ET Novo Nordisk recognized for diversity and inclusion

Novo Nordisk in the United States is honored to have been recognized for demonstrating a strategic and long-term commitment to fostering diversity...